BR112016017193A2 - Derivados de insulina, seus usos, e composição farmacêutica - Google Patents

Derivados de insulina, seus usos, e composição farmacêutica

Info

Publication number
BR112016017193A2
BR112016017193A2 BR112016017193A BR112016017193A BR112016017193A2 BR 112016017193 A2 BR112016017193 A2 BR 112016017193A2 BR 112016017193 A BR112016017193 A BR 112016017193A BR 112016017193 A BR112016017193 A BR 112016017193A BR 112016017193 A2 BR112016017193 A2 BR 112016017193A2
Authority
BR
Brazil
Prior art keywords
derivatives
pharmaceutical composition
insulin derivatives
insulin
diabetes
Prior art date
Application number
BR112016017193A
Other languages
English (en)
Inventor
Madsen Peter
HOSTRUP Susanne
Münzel Martin
Børglum Kjeldsen Thomas
Ulrich Hjørringgaard Claudia
Fledelius Christian
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112016017193A2 publication Critical patent/BR112016017193A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

DERIVADOS DE INSULINA, SEUS USOS, E COMPOSIÇÃO FARMACÊUTICA. A presente invenção pertence ao campo terapêutico de fármacos para condições médicas relacionadas à diabetes. Mais especificamente, a invenção refere-se a novos derivados acilados de análogos de insulina humana. A invenção também fornece composições farmacêuticas incluindo tais derivados de insulina, e refere-se ao uso de tais derivados para o tratamento ou prevenção de condições médicas relacionadas à diabetes.
BR112016017193A 2014-02-28 2015-02-26 Derivados de insulina, seus usos, e composição farmacêutica BR112016017193A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14157215 2014-02-28
PCT/EP2015/053989 WO2015128403A2 (en) 2014-02-28 2015-02-26 Novel insulin derivatives and the medical uses hereof

Publications (1)

Publication Number Publication Date
BR112016017193A2 true BR112016017193A2 (pt) 2017-10-03

Family

ID=50184804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017193A BR112016017193A2 (pt) 2014-02-28 2015-02-26 Derivados de insulina, seus usos, e composição farmacêutica

Country Status (23)

Country Link
US (1) US10040839B2 (pt)
EP (1) EP3110840B1 (pt)
JP (1) JP6580583B2 (pt)
KR (1) KR20160125988A (pt)
CN (1) CN106459171B (pt)
AR (1) AR099569A1 (pt)
AU (1) AU2015222135B2 (pt)
BR (1) BR112016017193A2 (pt)
CA (1) CA2941103A1 (pt)
DK (1) DK3110840T3 (pt)
ES (1) ES2831848T3 (pt)
HR (1) HRP20201732T1 (pt)
HU (1) HUE051355T2 (pt)
IL (1) IL246757B (pt)
MX (1) MX368387B (pt)
PL (1) PL3110840T3 (pt)
PT (1) PT3110840T (pt)
RS (1) RS61137B1 (pt)
RU (1) RU2684456C2 (pt)
SA (1) SA516371705B1 (pt)
SI (1) SI3110840T1 (pt)
TW (1) TWI686403B (pt)
WO (1) WO2015128403A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170028031A1 (en) * 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
CA2996455A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
US11208453B2 (en) * 2016-11-21 2021-12-28 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
KR101909052B1 (ko) * 2017-02-09 2018-10-17 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
MA49896A (fr) * 2017-08-17 2020-06-24 Novo Nordisk As Nouveaux analogues d'insuline acylés et leurs utilisations
US20190290736A1 (en) 2017-10-19 2019-09-26 Fourward Technology, LLC Topical composition for improved healing of open wounds
AU2019398579A1 (en) 2018-12-11 2021-07-29 Sanofi Peptide binder
US20220125941A1 (en) * 2019-02-13 2022-04-28 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof
CA3148536A1 (en) * 2019-08-27 2021-03-04 Anne Pernille Tofteng SHELTON Compstatin analogues and their medical uses
MX2022006251A (es) 2019-12-11 2022-06-22 Novo Nordisk As Analogos de insulina novedosos y usos de estos.
KR20240013778A (ko) * 2021-05-24 2024-01-30 선샤인 레이크 파르마 컴퍼니 리미티드 신규한 아실화된 인슐린 유사체

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
ES2072596T3 (es) * 1989-12-21 1995-07-16 Novo Nordisk As Preparaciones de insulina que contienen acido nicotinico o nicotinamida.
WO1995007931A1 (en) 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
WO1996029344A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
CN1259142A (zh) 1997-03-20 2000-07-05 诺沃挪第克公司 用于肺部的无锌胰岛素结晶组合物
CA2306877A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
EP1025125B1 (en) 1997-10-24 2003-06-25 Novo Nordisk A/S Aggregates of human insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
JP2002500196A (ja) 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ 安定化させたインスリン組成物
JP2002518408A (ja) 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン インスリン類似体
WO2001000675A1 (en) 1999-06-29 2001-01-04 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
AU2001264789A1 (en) 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP2005526009A (ja) 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
PL374949A1 (en) 2001-12-20 2005-11-14 Eli Lilly And Company Insulin molecule having protracted time action
WO2003075950A1 (en) 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
US20060217290A1 (en) 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
US20060183667A1 (en) 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
PL2107069T3 (pl) 2003-08-05 2013-06-28 Novo Nordisk As Nowe pochodne insuliny
AU2004264958B2 (en) 2003-08-13 2010-04-15 Biocon, Ltd Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP2292653B1 (en) 2005-02-02 2014-05-21 Novo Nordisk A/S Novel insulin derivatives
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
EP2076242B8 (en) 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
KR101729986B1 (ko) * 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009015456A1 (en) 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
KR20100053561A (ko) 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
ES2543393T3 (es) 2007-11-08 2015-08-18 Novo Nordisk A/S Derivado de insulina
US8937042B2 (en) 2007-11-16 2015-01-20 Novo Nordisk A/S Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
WO2009112583A2 (en) * 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910569B1 (en) * 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
ES2611040T3 (es) 2009-06-30 2017-05-04 Novo Nordisk A/S Derivados de insulina
KR101759499B1 (ko) * 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 지속형 인슐린 조성물
KR20130092972A (ko) 2010-05-10 2013-08-21 노보 노르디스크 에이/에스 인슐린-아연 복합체의 제조 방법
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
WO2011161125A1 (en) * 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
CN103596584B (zh) * 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
CN104010652A (zh) 2011-10-27 2014-08-27 卡斯西部储备大学 超浓缩的速效胰岛素类似物制剂

Also Published As

Publication number Publication date
RU2684456C2 (ru) 2019-04-09
JP6580583B2 (ja) 2019-09-25
HUE051355T2 (hu) 2021-03-01
AR099569A1 (es) 2016-08-03
IL246757A0 (en) 2016-08-31
RU2016135543A3 (pt) 2018-08-30
CA2941103A1 (en) 2015-09-03
EP3110840B1 (en) 2020-10-21
HRP20201732T1 (hr) 2020-12-25
SI3110840T1 (sl) 2020-12-31
PL3110840T3 (pl) 2021-04-06
WO2015128403A2 (en) 2015-09-03
CN106459171B (zh) 2020-12-15
JP2017508741A (ja) 2017-03-30
IL246757B (en) 2020-04-30
SA516371705B1 (ar) 2019-10-08
ES2831848T3 (es) 2021-06-09
MX368387B (es) 2019-10-01
RS61137B1 (sr) 2020-12-31
EP3110840A2 (en) 2017-01-04
AU2015222135B2 (en) 2018-12-20
RU2016135543A (ru) 2018-03-30
US10040839B2 (en) 2018-08-07
CN106459171A (zh) 2017-02-22
MX2016010899A (es) 2016-11-18
DK3110840T3 (da) 2020-11-02
PT3110840T (pt) 2020-11-26
US20170008945A1 (en) 2017-01-12
WO2015128403A3 (en) 2015-12-10
KR20160125988A (ko) 2016-11-01
TW201620930A (zh) 2016-06-16
TWI686403B (zh) 2020-03-01
AU2015222135A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
BR112016017193A2 (pt) Derivados de insulina, seus usos, e composição farmacêutica
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018002416A2 (pt) derivados de insulina e seus usos médicos
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
IN2014MN02056A (pt)
BR112016027435A2 (pt) formulação inovadora de meloxicam
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл
CO2022007273A2 (es) Análogos de insulina novedosos y usos de estos
BR112017001803A2 (pt) aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos
BR112016029619A8 (pt) Compostos da classe de fluoroquinolonas, composição farmacêutica e medicamento compreendendo tais compostos e usos de tais compostos
BR112018007269A2 (pt) compostos de oxa-diazaespiro tendo atividade contra dor
BR112017003881A2 (pt) derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B10A Cessation: cessation confirmed
B350 Update of information on the portal [chapter 15.35 patent gazette]